NCT00323752

Brief Summary

The purpose of this study is to establish whether rHuEpo is as effective as PAD in increasing red cell mass prior to surgery. Other benefits of the PAD program and preoperative administration of rHuEpo will also be compared.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Oct 2004

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2004

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

May 8, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 9, 2006

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2007

Completed
Last Updated

September 25, 2008

Status Verified

September 1, 2008

Enrollment Period

3.2 years

First QC Date

May 8, 2006

Last Update Submit

September 24, 2008

Conditions

Keywords

Blood loss, Erythropoetin

Outcome Measures

Primary Outcomes (1)

  • Red cell mass at start of surgery

    21 days

Secondary Outcomes (1)

  • Requirement for blood transfusion

    21 days

Interventions

rHuEpoPROCEDURE

Subjects will be randomly assigned to either participate in the PAD program or receive the rHuEpo treatment. Subjects in the PAD group will donate 1 unit of blood at -14 and -7 days prior to surgery. A dose of 500 IU of rHuEpo will be administered subcutaneously to subjects in the rHuEpo group at -21, -14, and -7 days prior to surgery.

Eligibility Criteria

Age12 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Scoliosis repair

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

British Columbia Children's Hospital

Vancouver, British Columbia, Canada

Location

MeSH Terms

Conditions

ScoliosisHemorrhage

Condition Hierarchy (Ancestors)

Spinal CurvaturesSpinal DiseasesBone DiseasesMusculoskeletal DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Eleanor Reimer, MD

    The University of British Columbia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 8, 2006

First Posted

May 9, 2006

Study Start

October 1, 2004

Primary Completion

December 1, 2007

Study Completion

December 1, 2007

Last Updated

September 25, 2008

Record last verified: 2008-09

Locations